Formula including tetrapeptide and tripeptide mixture

A technology of formula and content, applied in the field of cosmetics and personal care products, can solve the problems of no improvement in this characteristic, no collagen stimulation effect of dipeptide, etc.

Inactive Publication Date: 2007-01-10
SEDERMA SA
View PDF87 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the dipeptide did not have a significant collagen-stimulating effect, and the combination did not see any improvement in this property compared to the tetrapeptide alone

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Formula including tetrapeptide and tripeptide mixture
  • Formula including tetrapeptide and tripeptide mixture
  • Formula including tetrapeptide and tripeptide mixture

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0302] Example 1: Anti-Wrinkle Night Cream

[0303] Product INCI Name %

[0304] Phase A

[0305] h 2 O 70.95

[0306] Ultrez 10 Carbomer 0.15

[0307] Phase B

[0308] Glycerine Glycerine 3.50

[0309] Phase C

[0310] Volpo S2 Steareth 2 0.40

[0311] Crodafos CES Cetearyl alcohol dicetyl

[0312] phosphate & ceteth

[0313] 10 phosphate 4.00

[0314] DC 345 Cyclohexasiloxane 2.00

[0315] Crodamol OSU Dioctyl succinate 7.00

[0316] Volpo S 10 Steareth 10 1.20

[0317] Nipastat Mixed parabens 0.30

[0318] D phase

[0319] Sorbate Sorbate Sorbate 0.10

[0320] Phase E

[0321] h 2 O 2.50

[0322] NaOH 38% Sodium hydroxide 0.30

[0323] F phase

[0324] Perfume Fragrance Fragrance 0.10

[0325] G phase

[0326] MATRIXYL® 3000 *) 3.00

[0327] The emulsion is prepared as follows: Phase A: Disperse Ultrez 10 in water and let it swell for 20 minutes, then add phase B; heat to 75°C B; heat phase C separately ...

example 2

[0330] Example 2: Decrease in the wrinkles around the eyes (in vivo)

[0331] Fifteen middle-aged female volunteers with wrinkles around the eyes participated in a study using the cream of Example 1. Wrinkles around the eyes were measured by questionnaires, a self-assessment scale and standard skin replication. Briefly, the method involves applying a polymer to the eye area which, when hardened, can be peeled away to reveal a "negative" contour of the skin surface. The contour instrument is then used to measure wrinkle depth, length, volume, etc. Then, according to the subject, the participants applied the cream product of Example 1 to the target area of ​​one eye twice a day for 56 days; the other eye was coated with a control without peptide. The amount applied varies by subject. However, the amount should be the same for both eyes. Replicate assays were performed from day 0 to day 56. The results showed that in the eye area where the prescription of Example 1 was appli...

example 3

[0332] Example 3: Increase in synthesis of collagen (in vitro)

[0333]Human dermal fibroblasts were enriched with vitamin C (1.5 and 15 ppm) in the presence of the peptide N-palmitoyl-glycine-glutamine-proline-arginine (SEQ ID NO: 3). The peptides were cultured in two mediums for 72 hours, and there were two concentrations of peptides, namely 2.5ppm and 3.6ppm. After incubation, the medium was collected and the viability of the cells was assessed by the MTT assay. Collagen assays of each cell lysate were then performed by ELISA. The test was performed 3 times.

[0334] At the same time, a negative control should be tested under the same conditions but without the peptide.

[0335] The table of results in Table 2 below shows an increase in gelatin synthesis compared to the blank (no peptide) test:

[0336] N-Palmitoyl-Glycine-Glutamine-Proline-Arginine Concentration

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to view more

Abstract

Pharmaceutical, personal care and cosmetic compositions containing a tripeptide and a tetrapeptide are useful for treating visible signs of aging including wrinkles, stretch marks and dark circles.

Description

technical field [0001] The present invention relates to cosmetic and personal care products. Background technique [0002] The first signs of aging are often reflected in the body's skin: dryness, fine lines and wrinkles, age spots, erythema, sagging and loss of vitality. Dullness and hair loss are also well-known signs. There are many skin and hair care products on the market that consumers can use to treat or prevent these skin conditions caused by extrinsic stressors. These external sources include, but are not limited to: air pollution, mechanical stress, exposure to household items or other chemicals, sun exposure (aging), and sunburn. In addition, of course, intrinsic stress causes such as acne, dietary influences and general progressive aging are included. [0003] The skin is constantly exposed to these extrinsic environments and as a result visible signs of skin aging and damage such as wrinkles and dryness, thinning and other histological changes appear. As ski...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K8/64A61Q19/08A61K8/66A61K38/06A61K38/07A61Q7/00A61Q19/00
CPCA61K8/64A61Q19/00A61K8/66A61K38/06A61Q7/00A61Q19/08A61K38/07A61K2300/00C07K5/08C07K5/10
Inventor 卡尔·林特纳
Owner SEDERMA SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap